• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
PublishGo to AppAI Superconnector
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    Guardant Health to Participate in Upcoming Investor Conferences

    11/7/25 8:00:00 AM ET
    $GH
    Medical Specialities
    Health Care
    Get the next $GH alert in real time by email

    Guardant Health, Inc. (NASDAQ:GH), a leading precision oncology company, today announced the company will be participating in the following investor conferences.

    • Jefferies Global Healthcare Conference in London, UK

      Fireside chat on Wednesday, November 19 at 9:30 a.m. Greenwich Mean Time

    • Piper Sandler 37th Annual Healthcare Conference in New York, NY

      Fireside chat on Tuesday, December 2 at 8:30 a.m. Eastern Time

    Interested parties may access live and archived webcasts of the sessions on the "Investors" section of the company website at: www.guardanthealth.com.

    About Guardant Health

    Guardant Health is a leading precision oncology company focused on guarding wellness and giving every person more time free from cancer. Founded in 2012, Guardant is transforming patient care and accelerating new cancer therapies by providing critical insights into what drives disease through its advanced blood and tissue tests, real-world data and AI analytics. Guardant tests help improve outcomes across all stages of care, including screening to find cancer early, monitoring for recurrence in early-stage cancer, and treatment selection for patients with advanced cancer. For more information, visit guardanthealth.com and follow the company on LinkedIn, X (Twitter) and Facebook.

    Source: Guardant Health, Inc.

    View source version on businesswire.com: https://www.businesswire.com/news/home/20251106513309/en/

    Investor Contact:

    Zarak Khurshid

    [email protected]

    Media Contact:

    Meaghan Smith

    [email protected]

    Get the next $GH alert in real time by email

    Crush Q3 2025 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $GH

    DatePrice TargetRatingAnalyst
    9/25/2025$75.00Peer Perform → Outperform
    Wolfe Research
    9/22/2025$72.00Overweight
    Wells Fargo
    4/10/2025$55.00Outperform
    Mizuho
    1/23/2025$60.00Overweight
    Barclays
    6/28/2024$36.00Neutral → Buy
    Guggenheim
    6/3/2024$32.00Buy
    Jefferies
    4/24/2024$28.00Buy
    Craig Hallum
    12/14/2023Neutral
    Guggenheim
    More analyst ratings

    $GH
    SEC Filings

    View All

    Guardant Health Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement

    8-K - Guardant Health, Inc. (0001576280) (Filer)

    11/7/25 5:17:52 PM ET
    $GH
    Medical Specialities
    Health Care

    SEC Form 424B5 filed by Guardant Health Inc.

    424B5 - Guardant Health, Inc. (0001576280) (Filer)

    11/6/25 4:34:10 PM ET
    $GH
    Medical Specialities
    Health Care

    SEC Form FWP filed by Guardant Health Inc.

    FWP - Guardant Health, Inc. (0001576280) (Subject)

    11/5/25 8:42:28 AM ET
    $GH
    Medical Specialities
    Health Care

    $GH
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Guardant Health to Participate in Upcoming Investor Conferences

    Guardant Health, Inc. (NASDAQ:GH), a leading precision oncology company, today announced the company will be participating in the following investor conferences. Jefferies Global Healthcare Conference in London, UK Fireside chat on Wednesday, November 19 at 9:30 a.m. Greenwich Mean Time Piper Sandler 37th Annual Healthcare Conference in New York, NY Fireside chat on Tuesday, December 2 at 8:30 a.m. Eastern Time Interested parties may access live and archived webcasts of the sessions on the "Investors" section of the company website at: www.guardanthealth.com. About Guardant Health Guardant Health is a leading precision oncology company focused on guarding wellness and giving every

    11/7/25 8:00:00 AM ET
    $GH
    Medical Specialities
    Health Care

    Guardant Health Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

    Guardant Health, Inc. (NASDAQ:GH), a leading precision oncology company, today announced that on October 21, 2025, the Compensation Committee of Guardant's Board of Directors approved the granting of restricted stock units ("RSUs") representing 184,961 shares of its common stock to 272 new non-executive employees and one non-qualified stock option award to purchase 5,731 shares of its common stock to one new non-executive employee with a grant date of October 31, 2025 under the Guardant Health, Inc. 2023 Employment Inducement Incentive Award Plan (the "Inducement Plan"). The RSUs and stock options were granted as inducements material to the employees entering into employment with Guardant i

    11/6/25 6:35:00 PM ET
    $GH
    Medical Specialities
    Health Care

    New Study Validates Guardant Reveal Blood Test's Effectiveness in Monitoring Chemotherapy Response

    Tissue-free Guardant Reveal test identifies disease progression up to 18 months earlier than standard clinical measures in patients with advanced cancer Longitudinal circulating tumor DNA (ctDNA) monitoring across multiple timepoints provides a more accurate prediction of treatment response and disease progression than a single on-treatment analysis, reinforcing the clinical value of serial testing Guardant Health, Inc. (NASDAQ:GH), a leading precision oncology company, today announced new data demonstrating that its Guardant Reveal® blood test helps clinicians to assess the effectiveness of chemotherapy in patients with advanced solid tumors months earlier than conventional methods. T

    11/6/25 8:05:00 AM ET
    $GH
    Medical Specialities
    Health Care

    $GH
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Guardant Health upgraded by Wolfe Research with a new price target

    Wolfe Research upgraded Guardant Health from Peer Perform to Outperform and set a new price target of $75.00

    9/25/25 8:22:52 AM ET
    $GH
    Medical Specialities
    Health Care

    Wells Fargo resumed coverage on Guardant Health with a new price target

    Wells Fargo resumed coverage of Guardant Health with a rating of Overweight and set a new price target of $72.00

    9/22/25 8:30:36 AM ET
    $GH
    Medical Specialities
    Health Care

    Mizuho initiated coverage on Guardant Health with a new price target

    Mizuho initiated coverage of Guardant Health with a rating of Outperform and set a new price target of $55.00

    4/10/25 12:41:47 PM ET
    $GH
    Medical Specialities
    Health Care

    $GH
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Director Krognes Steve E. converted options into 154 shares, increasing direct ownership by 0.84% to 18,436 units (SEC Form 4)

    4 - Guardant Health, Inc. (0001576280) (Issuer)

    11/3/25 5:45:36 PM ET
    $GH
    Medical Specialities
    Health Care

    Director Mignone Roberto converted options into 3,167 shares (SEC Form 4)

    4 - Guardant Health, Inc. (0001576280) (Issuer)

    10/22/25 7:07:55 PM ET
    $GH
    Medical Specialities
    Health Care

    Director Hidalgo Medina Manuel converted options into 232 shares, increasing direct ownership by 21% to 1,315 units (SEC Form 4)

    4 - Guardant Health, Inc. (0001576280) (Issuer)

    10/20/25 7:50:40 PM ET
    $GH
    Medical Specialities
    Health Care

    $GH
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Kalia Kumud bought $38,963 worth of shares (2,187 units at $17.82), increasing direct ownership by 21% to 12,722 units (SEC Form 4)

    4 - Guardant Health, Inc. (0001576280) (Issuer)

    3/19/24 5:29:06 PM ET
    $GH
    Medical Specialities
    Health Care

    $GH
    FDA approvals

    Live FDA approvals issued by the Food and Drug Administration and FDA breaking news

    View All

    July 30, 2024 - FDA Roundup: July 30, 2024

    For Immediate Release: July 30, 2024 Today, the U.S. Food and Drug Administration is providing an at-a-glance summary of news from around the agency:  Today, the FDA is announcing the fiscal year (FY) 2025 user fee rates for importers approved to participate in the Voluntary Qualified Importer Program (VQIP) and accreditation and certification bodies interested in participating in the Accredited Third-Party C

    7/30/24 3:38:18 PM ET
    $GH
    Medical Specialities
    Health Care

    May 28, 2021 - FDA Approves First Targeted Therapy for Lung Cancer Mutation Previously Considered Resistant to Drug Therapy

    For Immediate Release: May 28, 2021 Today, the U.S. Food and Drug Administration approved Lumakras (sotorasib) as the first treatment for adult patients with non-small cell lung cancer whose tumors have a specific type of genetic mutation called KRAS G12C and who have received at least one prior systemic therapy. This is the first approved targeted therapy for tumors with any KRAS mutation, which accounts for ap

    5/28/21 1:05:48 PM ET
    $AMGN
    $GH
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care
    Medical Specialities

    May 21, 2021 - FDA Approves First Targeted Therapy for Subset of Non-Small Cell Lung Cancer

    For Immediate Release: May 21, 2021 Today, the U.S. Food and Drug Administration approved Rybrevant (amivantamab-vmjw) as the first treatment for adult patients with non-small cell lung cancer whose tumors have specific types of genetic mutations: epidermal growth factor receptor (EGFR) exon 20 insertion mutations. The FDA also approved the Guardant360 CDx (Guardant Health Inc.) as a companion diagnostic for Ry

    5/21/21 12:50:51 PM ET
    $JNJ
    $GH
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Medical Specialities

    $GH
    Leadership Updates

    Live Leadership Updates

    View All

    Alex M. Azar II Joins Guardant Health Board of Directors

    Guardant Health, Inc. (NASDAQ:GH), a leading precision oncology company, today announced the appointment of Alex M. Azar II to its board of directors, effective immediately. As the 24th Secretary of the U.S. Department of Health and Human Services (HHS), Secretary Azar had oversight and management of agencies critical to all Americans' health care including the Centers for Medicare and Medicaid Services, the Food and Drug Administration, and the Center for Disease Control and Prevention. "We're honored to welcome Secretary Azar to Guardant's board," said Helmy Eltoukhy, chairman and co-CEO of Guardant Health. "Secretary Azar has served at the senior-most levels of government as well as th

    9/15/25 4:07:00 PM ET
    $GH
    Medical Specialities
    Health Care

    Guardant Health Joins Forces With Dak Prescott's Faith Fight Finish Foundation and Feist-Weiller Cancer Center's Partners in Wellness to Boost Colon Cancer Screening in Underserved Communities

    Foundation's grant to mobile cancer screening program in Louisiana allows individuals to be screened with Guardant's Shield™ blood test in their own community Mobile screening events to be held during Colorectal Cancer Awareness Month (March) throughout northern and central Louisiana Guardant Health, Inc. (NASDAQ:GH), a leading precision oncology company, today announced a collaboration with Dak Prescott's Faith Fight Finish Foundation and the mobile cancer screening program, Partners in Wellness, an initiative of LSU Health Shreveport and Ochsner LSU Health—Feist-Weiller Cancer Center, to increase colorectal cancer screening rates in northern and central Louisiana. This press release

    3/5/25 8:05:00 AM ET
    $GH
    Medical Specialities
    Health Care

    Roberto A. Mignone Joins Guardant Health Board of Directors

    Guardant Health, Inc. (NASDAQ:GH), a pioneer in precision oncology, today announced the appointment of Roberto A. Mignone to its board of directors, effective immediately. Mr. Mignone is the Founder and Managing Partner of Bridger Management LLC, an investment management firm founded in 2000 and specializing in long-term equity strategies. "We are fortunate to welcome Roberto Mignone to our board of directors, bringing his healthcare industry expertise, long-term vision, and business acumen to our company," said Helmy Eltoukhy, chairman and co-CEO of Guardant Health. "We look forward to Mr. Mignone's perspective as we strengthen our product offerings across the continuum of care, and look

    10/24/24 5:05:00 PM ET
    $GH
    Medical Specialities
    Health Care

    $GH
    Financials

    Live finance-specific insights

    View All

    Guardant Health Reports Third Quarter 2025 Financial Results and Increases 2025 Revenue Guidance

    Revenue growth of 39% broadly driven by strong performance across Oncology, Screening, and Biopharma & Data Raises 2025 revenue guidance to $965 to $970 million, representing year-over-year growth of 31% Guardant Health, Inc. (NASDAQ:GH), a leading precision oncology company, today reported financial results for the quarter ended September 30, 2025. Third Quarter 2025 Financial Highlights For the three-month period ended September 30, 2025, as compared to the same period of 2024: Reported total revenue of $265.2 million, an increase of 39%, driven by: Oncology revenue of $184.4 million, an increase of 31%, and approximately 74,000 oncology tests, an increase of 40% Screeni

    10/29/25 4:05:00 PM ET
    $GH
    Medical Specialities
    Health Care

    Guardant Health to Share Data Supporting Critical Role of Blood-Based Testing in Improving Cancer Screening Adherence at ACG 2025

    Expanded cohort reiterates strong adherence rate of over 90% for Shield blood-based colorectal cancer screening test Survey findings show eligible individuals prefer a blood test for colorectal cancer and lung cancer compared with traditional screening methods Guardant Health, Inc. (NASDAQ:GH), a leading precision oncology company, today announced the company and its research collaborators will present data showing the critical role of blood-based testing in increasing cancer screening adherence at the American College of Gastroenterology (ACG) 2025 Annual Meeting in Phoenix, Arizona taking place Friday, October 24 – Wednesday, October 29, 2025. Building off findings from Guardant

    10/26/25 3:01:00 PM ET
    $GH
    Medical Specialities
    Health Care

    Guardant Health to Report Third Quarter 2025 Financial Results on October 29, 2025

    Guardant Health, Inc. (NASDAQ:GH), a leading precision oncology company, today announced it will report financial results for the third quarter 2025 after market close on Wednesday, October 29, 2025. Company management will webcast a corresponding conference call beginning at 1:30 p.m. Pacific Time / 4:30 p.m. Eastern Time. Live audio of the webcast will be available on the "Investors" section of the company website at: www.guardanthealth.com. The webcast will be archived and available for replay after the event. About Guardant Health Guardant Health is a leading precision oncology company focused on guarding wellness and giving every person more time free from cancer. Founded in 2012

    10/9/25 4:05:00 PM ET
    $GH
    Medical Specialities
    Health Care

    $GH
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    SEC Form SC 13G filed by Guardant Health Inc.

    SC 13G - Guardant Health, Inc. (0001576280) (Subject)

    11/13/24 7:34:17 PM ET
    $GH
    Medical Specialities
    Health Care

    SEC Form SC 13G filed by Guardant Health Inc.

    SC 13G - Guardant Health, Inc. (0001576280) (Subject)

    11/8/24 10:46:38 AM ET
    $GH
    Medical Specialities
    Health Care

    Amendment: SEC Form SC 13G/A filed by Guardant Health Inc.

    SC 13G/A - Guardant Health, Inc. (0001576280) (Subject)

    7/5/24 10:32:48 AM ET
    $GH
    Medical Specialities
    Health Care